Ignite Creation Date:
2025-12-24 @ 4:01 PM
Ignite Modification Date:
2026-01-25 @ 5:47 AM
Study NCT ID:
NCT00987766
Status:
COMPLETED
Last Update Posted:
2017-07-02
First Post:
2009-09-30
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
Sponsor:
Vanderbilt-Ingram Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-11
Start Date Type:
None
Primary Completion Date:
2013-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-10
Completion Date Type:
ACTUAL
First Submit Date:
2009-09-30
First Submit QC Date:
None
Study First Post Date:
2009-10-01
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-06-29
Last Update Post Date:
2017-07-02
Last Update Post Date Type:
ACTUAL